Abbvie's Allergan Says Phase 3 Trial of Vuity in Presbyopia Had Positive Results

• (PLX AI) - Abbvie's Allergan Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia).
• • In the VIRGO trial evaluating twice-daily administration of VUITY, the primary endpoint of improving near vision without compromising distance vision at Day 14, Hour 9 was met
• • Data from the VIRGO trial will be presented at upcoming medical congresses and serve as the basis for a supplemental U.S. New Drug Application submission in the second quarter of 2022